June 2024 in “Dermatology and therapy” This study reviewed recent advancements in using botulinum toxin for treating androgenetic alopecia and emphasized the need for further research to determine the most effective injection sites and depths, as current strategies show inconsistent results.
May 2024 in “Nano letters” This study developed a quercetin-encapsulated and polydopamine-integrated nanosystem that reshapes the perifollicular microenvironment, showing potential for rescuing hair follicle viability and regenerating hair follicles in androgenic alopecia by scavenging reactive oxygen species and promoting angiogenesis.
April 2024 in “Nigerian Postgraduate Medical Journal” This review summarizes existing knowledge on androgenetic alopecia, including its epidemiology, pathophysiology, and management, but presents no new research findings.
April 2024 in “Animal models and experimental medicine” The researchers reported that platelet-rich plasma treatment increased hair growth in androgenic alopecia patients, potentially by altering scalp microbiota composition, including increased Cutibacterium and decreased Staphylococcus and Lawsonella.
July 2023 in “International journal of trichology” In this study, no significant association was found between the severity of androgenetic alopecia in males and trichoscopy features such as hair diameter diversity, vellus hair, and white dots, suggesting that trichoscopy may not predict alopecia severity based on the Hamilton–Norwood scale.
June 2023 in “Stem cell reviews and reports” This review summarizes current methods, effectiveness, and clinical progress of stem cell therapies for androgenetic alopecia, highlighting their potential for hair regrowth and follicle repair despite unclear long-term effects and mechanisms.
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
This review suggests that stem cells might be a promising addition or alternative to standard treatments for androgenic alopecia, but larger studies are needed to confirm these findings.
8 citations
,
October 2022 in “Regenerative Therapy” This review discusses regenerative medicine approaches for treating alopecia, including mesenchymal stem cell therapies and platelet-rich plasma, but reports no new clinical results, emphasizing the need for further study.
2 citations
,
August 2022 in “Aesthetic Plastic Surgery” June 2022 in “Journal of Cosmetic Dermatology” This study found that combining botulinum toxin A injections with finasteride and minoxidil increased hair density in patients with androgenic alopecia more effectively than finasteride and minoxidil alone.
18 citations
,
March 2022 in “Drug design, development and therapy” This review examines the definition, classification, mechanism, clinical efficacy for hair regrowth, and potential adverse effects of platelet rich plasma, but does not present new experimental results.
2 citations
,
December 2021 in “Dermatology and therapy” This review reports that clinical studies generally showed favorable results for microneedling as an adjunct therapy for androgenic alopecia and alopecia areata, despite the low quality of existing data.
24 citations
,
September 2020 in “Dermatology and therapy” This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.
14 citations
,
September 2020 in “Dermatologic Therapy” This study reported that oral minoxidil improved hair density and had an acceptable safety profile in women with androgenetic alopecia.
33 citations
,
July 2020 in “Journal of The American Academy of Dermatology” In this study, PRP increased hair density in areas treated for androgenetic alopecia, but there was no significant difference when compared to placebo-treated areas.
15 citations
,
April 2020 in “Journal of The American Academy of Dermatology” In this study, intradermal injection of botulinum toxin was associated with increased hair growth in men with androgenetic alopecia through the suppression of TGF-β1 secretion from dermal papilla cells.
19 citations
,
April 2020 in “Dermatologic Therapy” This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.
16 citations
,
March 2020 in “Journal of The American Academy of Dermatology” This abstract discusses the efficacy of spironolactone, cyproterone acetate, and flutamide in treating female pattern hair loss, noting that flutamide use requires caution due to potential liver toxicity, especially at high doses.
8 citations
,
October 2019 in “Dermatologic Therapy” This source explores the potential use of oral bicalutamide for treating female pattern hair loss, but specific results or outcomes from the study are not reported in the abstract.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Clascoterone safely promotes hair growth similar to minoxidil.
13 citations
,
August 2018 in “Facial Plastic Surgery Clinics of North America” This review discusses the potential effectiveness of cell therapy for hair loss, highlighting promising early findings but emphasizing that more research is needed to explore specific therapies like autologous fat grafting and mesenchymal stem cells.
53 citations
,
June 2017 in “Skin appendage disorders” This review suggests that platelet-rich plasma may be effective in increasing hair density in patients with androgenetic alopecia, but more research is needed to determine the best treatment protocol.
153 citations
,
March 2017 in “Endocrine” This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.
133 citations
,
February 2017 in “PLoS Genetics” In this study, researchers used genetic data from over 52,000 men to identify over 250 genetic loci associated with severe hair loss and developed a predictive algorithm for determining hair loss risk.
37 citations
,
May 2016 in “Deutsches Arzteblatt International” This review outlines various causes and manifestations of hair loss, highlighting that each type has distinct underlying mechanisms and requires specific treatment approaches, without reporting new clinical results.
11 citations
,
September 2013 in “Journal of the Egyptian Women's Dermatologic Society (Print)” Various treatments exist for hair loss, but more research is needed for better options.
74 citations
,
January 2013 in “Journal of Investigative Dermatology” Four genetic risk spots found for hair loss, with WNT signaling involved and a link to curly hair.
185 citations
,
March 2011 in “The Journal of Sexual Medicine” This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.
